FDA favors innovative heart valve for the frail

By MATTHEW PERRONE , AP Health Writer

The first artificial heart valve designed to be implanted without major surgery appears to help patients who are too frail to undergo chest-opening surgery, according to federal health reviewers.

The posted its review Monday of a highly anticipated heart valve from Edwards Lifesciences that can be threaded into place through one of the body's major arteries. Cardiologists hope this approach could offer a new option for patients who aren't healthy enough to undergo the more invasive open-heart , which has been used to replace valves for decades.

FDA says 20 percent more patients who received Edwards' valve were living after one year than patients who received traditional medical care. However, scientists also said patients receiving the device had higher rates of stroke and bleeding in the brain.

The agency will ask a panel of heart doctors to weigh in on these risks at a meeting Wednesday, though the agency is not required to follow the group's advice.

Edwards will eventually seek to market its valve for patients who are healthy enough for open-heart surgery. But because the valve is an , it was initially studied for patients with no other options.

Some 300,000 Americans have a diseased aortic heart valve, forcing the heart to work harder to squeeze blood through. Eventually the condition can lead to , and sudden death. More than 50,000 people a year undergo open-heart surgery to replace the valve, and thousands more are turned away, deemed too old or ill to survive the operation.

The surgery involves sawing the patient's breastbone in half, stopping the heart, cutting out the old valve and sewing a new one into place.

Edwards' Sapien valve, which is already available in Europe, is threaded through a leg artery up to the heart and then propped open and wedged into the aortic opening, replacing the natural heart valve.

Edwards will make the case for approving its device based on a study that showed nearly 70 percent of patients with the valve survived at least a year, compared with only 50 percent of those without it. However, FDA reviewers point out that little is known about patient survival after two years and longer-term safety studies are still needed. By contrast, patients who receive through open-heart surgery have been documented to live for decades.

FDA raises concerns that neurological side effects were more than three times higher among patients with the Sapien valve than for patients in the control group. Fourteen percent of patients with the valve experienced stroke, hemorrhaging or other brain-related problems. That compared to just 4.5 percent of patients who did not receive the valve. The FDA says these problems were actually probably underreported, since patients were assessed by a cardiology team rather than doctors specializing in brain injury.

Regulators suggest the stroke risk should be further analyzed in a follow-up study - even if the valve is approved. Edwards has proposed giving patients in that study a regimen of blood thinners to help reduce stroke risk.

If approved, Edwards is expected to charge about $30,000 for the valve, though hospital fees could bring the total cost of surgery closer to $70,000. Standard heart valve replacement costs upward of $50,000, mostly from surgical and hospitalization fees.

Shares of Irvine, Calif.-based Edwards Lifesciences Corp. rose 39 cents to $89.33 in morning trading.

0 shares

Related Stories

Heart valves implanted without open-heart surgery

date Jan 07, 2009

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center. Known as the PARTNER (Placement of ...

Study backs new heart valve without cracking chest

date Sep 22, 2010

(AP) -- Thousands of older Americans who need new heart valves but are too frail to survive the surgery might soon get a chance at an easier option - a way to thread in an artificial aortic valve without ...

Recommended for you

A-fib recurrence common five years after ablation

date 22 hours ago

(HealthDay)—Most patients with atrial fibrillation (AF) and systolic heart failure who undergo ablation have AF recurrence at five years, according to a study published in the April issue of the Journal of ...

Applied physics helps decipher the causes of sudden death

date Apr 17, 2015

Sudden cardiac death accounts for approximately 10% of natural deaths, most of which are due to ventricular fibrillation. Each year, it causes 300,000 deaths in the United States and 20,000 in Spain. Researchers have demonstrated ...

Cognitive problems are common after cardiac arrest

date Apr 17, 2015

Half of all patients who survive a cardiac arrest experience problems with cognitive functions such as memory and attention. This has been shown by a major international study led from Lund University. Surprisingly, however, ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.